Primary Resistance to Brigatinib in a Patient with Lung Adenocarcinoma Harboring ALK G1202R Mutation and LIPI-NTRK1 Rearrangement.

Zhiwei XiaoXuewu HuangBiyuan XieWenzhuan Xie Mengli Huang Li-Zhu Lin

Published in: OncoTargets and therapy (2020)

This paper provides new insights into the primary resistance to brigatinib in NSCLC patients carrying ALK G1202R mutation. The new fusion form of NTRK rearrangement was detected, which may provide potential treatment options after brigatinib resistance.

Keyphrases

advanced non small cell lung cancer
end stage renal disease
newly diagnosed
ejection fraction
small cell lung cancer
chronic kidney disease
prognostic factors
peritoneal dialysis
risk assessment
human health